XOMA Royalty (XOMA) Change in Acquisitions & Divestments (2012 - 2025)

XOMA Royalty (XOMA) reported Change in Acquisitions & Divestments of $1000.0 for Q4 2025, down 99.98% sequentially from $5.0 million in Q4 2014.

XOMA Royalty (XOMA) Change in Acquisitions & Divestments (2012 - 2025) Analysis & Trends

XOMA Royalty (XOMA) has 4 years of Change in Acquisitions & Divestments data on file, last reported at $1000.0 in Q4 2025.

For the quarter ending Q4 2025, Change in Acquisitions & Divestments changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Dec 2025 stood at $10.0 million (changed N/A YoY), and the FY2025 full-year result was $7.0 million, changed N/A from the prior year.
Change in Acquisitions & Divestments slipped to $1000.0 in Q4 2025, from $5.0 million in the prior quarter.
In the past five years, Change in Acquisitions & Divestments ranged from a high of $1000.0 in Q4 2025 to a low of $1000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	XOMA Royalty	478.42 Mn	412.34 Mn	-

Download Data